02269 Relative Valuation
02269's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, 02269 is overvalued; if below, it's undervalued.
Historical Valuation
WUXI BIO (02269) is now in the Fair zone, suggesting that its current forward PE ratio of 24.00 is considered Fairly compared with the five-year average of 45.93. The fair price of WUXI BIO (02269) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：36.44
Fair
24.00
PE
1Y
3Y
5Y
13.94
EV/EBITDA
WUXI BIO. (02269) has a current EV/EBITDA of 13.94. The 5-year average EV/EBITDA is 32.71. The thresholds are as follows: Strongly Undervalued below -23.50, Undervalued between -23.50 and 4.61, Fairly Valued between 60.81 and 4.61, Overvalued between 60.81 and 88.91, and Strongly Overvalued above 88.91. The current Forward EV/EBITDA of 13.94 falls within the Historic Trend Line -Fairly Valued range.
17.33
EV/EBIT
WUXI BIO. (02269) has a current EV/EBIT of 17.33. The 5-year average EV/EBIT is 41.04. The thresholds are as follows: Strongly Undervalued below -29.58, Undervalued between -29.58 and 5.73, Fairly Valued between 76.35 and 5.73, Overvalued between 76.35 and 111.66, and Strongly Overvalued above 111.66. The current Forward EV/EBIT of 17.33 falls within the Historic Trend Line -Fairly Valued range.
5.20
PS
WUXI BIO. (02269) has a current PS of 5.20. The 5-year average PS is 13.10. The thresholds are as follows: Strongly Undervalued below -10.64, Undervalued between -10.64 and 1.23, Fairly Valued between 24.97 and 1.23, Overvalued between 24.97 and 36.84, and Strongly Overvalued above 36.84. The current Forward PS of 5.20 falls within the Historic Trend Line -Fairly Valued range.
17.57
P/OCF
WUXI BIO. (02269) has a current P/OCF of 17.57. The 5-year average P/OCF is 34.89. The thresholds are as follows: Strongly Undervalued below -18.85, Undervalued between -18.85 and 8.02, Fairly Valued between 61.76 and 8.02, Overvalued between 61.76 and 88.62, and Strongly Overvalued above 88.62. The current Forward P/OCF of 17.57 falls within the Historic Trend Line -Fairly Valued range.
44.12
P/FCF
WUXI BIO. (02269) has a current P/FCF of 44.12. The 5-year average P/FCF is 44.19. The thresholds are as follows: Strongly Undervalued below -833.53, Undervalued between -833.53 and -394.67, Fairly Valued between 483.05 and -394.67, Overvalued between 483.05 and 921.91, and Strongly Overvalued above 921.91. The current Forward P/FCF of 44.12 falls within the Historic Trend Line -Fairly Valued range.
WUXI BIO (02269) has a current Price-to-Book (P/B) ratio of 2.72. Compared to its 3-year average P/B ratio of 2.87 , the current P/B ratio is approximately -5.21% higher. Relative to its 5-year average P/B ratio of 5.69, the current P/B ratio is about -52.15% higher. WUXI BIO (02269) has a Forward Free Cash Flow (FCF) yield of approximately 1.46%. Compared to its 3-year average FCF yield of 0.60%, the current FCF yield is approximately 142.17% lower. Relative to its 5-year average FCF yield of -0.00% , the current FCF yield is about -648334.54% lower.
2.72
P/B
Median3y
2.87
Median5y
5.69
1.46
FCF Yield
Median3y
0.60
Median5y
-0.00
Performance Decomposition
1Y
3Y
5Y
Market capitalization of 02269 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 02269 in the past 1 year is driven by Unknown.
People Also Watch
META
Meta Platforms Inc
646.06USD
-0.41%
XOM
Exxon Mobil Corp
122.91USD
3.73%
AAPL
Apple Inc
259.04USD
-0.50%
AVGO
Broadcom Inc
332.48USD
-3.21%
TSLA
Tesla Inc
435.8USD
1.02%
ORCL
Oracle Corp
189.65USD
-1.65%
NVDA
NVIDIA Corp
185.04USD
-2.15%
WMT
Walmart Inc
113.07USD
0.31%
AMZN
Amazon.com Inc
246.26USD
1.95%
MSFT
Microsoft Corp
478.11USD
-1.11%
Frequently Asked Questions
Is WUXI BIO (02269) currently overvalued or undervalued?
WUXI BIO (02269) is now in the Fair zone, suggesting that its current forward PE ratio of 24.00 is considered Fairly compared with the five-year average of 45.93. The fair price of WUXI BIO (02269) is between to according to relative valuation methord.
What is WUXI BIO (02269) fair value?
02269's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of WUXI BIO (02269) is between to according to relative valuation methord.
How does 02269's valuation metrics compare to the industry average?
The average P/S ratio for 02269's competitors is , providing a benchmark for relative valuation. WUXI BIO Corp (02269) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for WUXI BIO (02269) as of Jan 08 2026?
As of Jan 08 2026, WUXI BIO (02269) has a P/B ratio of 2.72. This indicates that the market values 02269 at 2.72 times its book value.
What is the current FCF Yield for WUXI BIO (02269) as of Jan 08 2026?
As of Jan 08 2026, WUXI BIO (02269) has a FCF Yield of 1.46%. This means that for every dollar of WUXI BIO’s market capitalization, the company generates 1.46 cents in free cash flow.
What is the current Forward P/E ratio for WUXI BIO (02269) as of Jan 08 2026?
As of Jan 08 2026, WUXI BIO (02269) has a Forward P/E ratio of 24.00. This means the market is willing to pay $24.00 for every dollar of WUXI BIO’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for WUXI BIO (02269) as of Jan 08 2026?
As of Jan 08 2026, WUXI BIO (02269) has a Forward P/S ratio of 5.20. This means the market is valuing 02269 at $5.20 for every dollar of expected revenue over the next 12 months.